Elevated Prevalence Of Pulmonary Arterial Hypertension (PAH) Driving Market Growth: Pivotal Factor Influencing Pulmonary Arterial Hypertension Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Pulmonary Arterial Hypertension Market Size Growth Forecast: What to Expect by 2025?
Over the past few years, the market size for pulmonary arterial hypertension has shown substantial growth. Projections show an expansion from $8.47 billion in 2024 to $9.15 billion in 2025, indicating a compound annual growth rate (CAGR) of 8.0%. The remarkable growth during the historic period can be traced back to factors such as an increase in the detection and understanding of pulmonary arterial hypertension (PAH), heightened healthcare spending, the growth of the elderly population, the development of more treatment options for pulmonary arterial hypertension, and an uptick in research and development activities centered around pulmonary hypertension.

How Will the Pulmonary Arterial Hypertension Market Size Evolve and Grow by 2029?
In the following years, the pulmonary arterial hypertension market is anticipated to witness substantial growth. It is projected to expand to "$12.69 billion by 2029 with a compound annual growth rate (CAGR) of 8.5%. Factors such as the adoption of new treatment methods for pulmonary arterial hypertension, better emphasis on early detection, a significant pipeline of PAH drugs and therapies, incorporation of precision medicine into PAH treatment, and enhancement of healthcare facilities in emerging markets contribute to this expected growth. Prominent trends in the predicted period encompass improvements in medical imaging and diagnostic technologies, cooperation for drug development, patient-centered strategies in managing pulmonary arterial hypertension, and an increased preference for combination therapy.

View the full report here:
https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

What Drivers Are Propelling the Growth of Pulmonary Arterial Hypertension Market Forward?
The rise in occurrence of pulmonary arterial hypertension (PAH) disease is a key factor driving the pulmonary arterial hypertension market's growth. A surge in PAH diseases and consequent patient hospitalizations for treatment will likely escalate the demand for corresponding medications in the projected period. Research by the National Organization for Rare Disorders, Inc. indicates that the US can expect to see around 500-1000 new cases of PAH every year, in line with one to two instances per million individuals. Europe is anticipated to witness comparable incidence rates.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5954&type=smp

Which Emerging Trends Are Transforming the Pulmonary Arterial Hypertension Market in 2025?
Key players in the pulmonary arterial hypertension market, like Winrevair, are stepping up their innovation game to provide better treatment opportunities and improved results for patients affected by this severe ailment. Merck & Co. Inc., a leading pharmaceutical multinational from the United States, launched Winrevair for the treatment of adults with pulmonary arterial hypertension in March 2024. Winrevair, having received approval from the US Food and Drug Administration (FDA), is the first therapeutic approach focusing on activin signaling for pulmonary arterial hypertension (PAH). This cutting-edge treatment method restores the equilibrium between pro- and anti-proliferative signals, managing the vascular cell proliferation associated with PAH, hence introducing a novel category of therapy for this condition.

What Are the Key Segments in the Pulmonary Arterial Hypertension Market?
The pulmonary arterial hypertension market covered in this report is segmented -

1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route Of Administration: Oral, Intravenous Or subcutaneous, Inhalational
3) By Distribution channel: Retail, Online

Subsegments:
1) By Endothelin Receptor Antagonists (ERAs): Bosentan, Ambrisentan, Macitentan
2) By PDE-5 Inhibitors: Sildenafil, Tadalafil
3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost
4) By SGC Stimulators: Riociguat

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=5954&type=smp

Who Are the Key Players Shaping the Pulmonary Arterial Hypertension Market's Competitive Landscape?
Major companies operating in the pulmonary arterial hypertension market include United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.

What Geographic Markets Are Powering Growth in the Pulmonary Arterial Hypertension Market?
North America was the largest region in the pulmonary arterial hypertension market in 2024. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=5954

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.